Amundi Asset Management US’s Apellis Pharmaceuticals APLS Stock Holding History

Amundi Asset Management US’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$313K	Hold	7,300	–	–	﹤0.01%	1407
2020 Q4	$418K	Hold	7,300	–	–	﹤0.01%	1318
2020 Q3	$220K	Buy	7,300 +3,700	+103%	+$111K	﹤0.01%	1376
2020 Q2	$118K	Buy	3,600 +1,100	+44%	+$35.3K	﹤0.01%	1430
2020 Q1	$67K	Buy	2,500 +1,000	+67%	+$35.5K	﹤0.01%	1455
2019 Q4	$46K	Hold	1,500	–	–	﹤0.01%	1573
2019 Q3	$36K	Buy	+1,500	New	+$41.3K	﹤0.01%	1577

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Amundi Asset Management US's APLS Position: Q1 2021 in Review

Amundi Asset Management US held its Apellis Pharmaceuticals (APLS) position steady in Q1 2021 at 7,300 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

Amundi Asset Management US first reported a position in APLS in Q3 2019 and has held it in 7 quarters since. The position peaked at $418K in Q4 2020. 175 funds tracked by Wall St. Rank hold APLS as of Q1 2021.

Amundi Asset Management US held 7,300 shares of Apellis Pharmaceuticals worth $313K as of Q1 2021.
Amundi Asset Management US left its Apellis Pharmaceuticals share count unchanged in Q1 2021.
Apellis Pharmaceuticals made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1407 holding.
Amundi Asset Management US first reported a position in Apellis Pharmaceuticals in Q3 2019 and has held it in 7 quarters since.
Amundi Asset Management US's Apellis Pharmaceuticals position peaked at $418K in Q4 2020.
175 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.